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Maintenance Therapy in Advanced Non-small
Cell Lung Cancer
Linda E. Coate, MD, and Frances A. Shepherd, MD, FRCPC
Abstract: Non-small cell lung cancer (NSCLC) is the leading cause
of cancer death in the industrialized world, and survival rates for
advanced disease remain low with standard platinum-based chemo-
therapy. One treatment strategy that has been investigated exten-
sively in NSCLC is that of “maintenance” therapy. Options for
maintenance include maintaining response to initial therapy by
continuing the initial combination chemotherapy regimen, continu-
ing only single agent chemotherapy, or by introducing a new agent.
Treatments that have been studied in randomized trials to date
include chemotherapy, molecularly targeted agents, and immuno-
therapy approaches. After the development of multiple new agents that
show activity in NSCLC and have a tolerable side effect profile, there
has been increasing interest recently in this treatment strategy. In this
study, we examine the evolution of this strategy by reviewing trials
investigating the main treatment paradigms used in maintenance ther-
apy for NSCLC.
(J Thorac Oncol. 2010;5: 723–734)
Non-small cell lung cancer (NSCLC) is the leading causeof cancer death in the industrialized world.1 The major-
ity of patients present with advanced disease for which
curative therapy is not available. The current standard of care
for treatment of advanced stage NSCLC is platinum-based
doublet chemotherapy, which results in modest prolongation
of survival and improvement in cancer-related symptoms, but
5% long-term survival at 5 years.2 Therefore, it is clear that
there is scope for improving the current treatment paradigm.
Maintenance therapy is one strategy that has been inves-
tigated extensively in recent years as a way of improving
outcomes in patients with NSCLC. The challenges that lie in
interpreting the literature come from the heterogeneity of studies
of maintenance chemotherapy and the lack of consensus with
respect to what constitutes maintenance treatment. This hetero-
geneity has become even more complex with the introduction of
molecularly targeted therapy for NSCLC.
For the purpose of this review, we have grouped studies
of maintenance chemotherapy under broad headings in an
effort to compare and contrast similar trials. The options for
maintenance chemotherapy in NSCLC include (1) continuing
induction chemotherapy for more cycles than the standard
(either by administering a predefined number of “extra”
cycles or continuing induction therapy until progression), (2)
continuing only the nonplatinum component of induction
therapy, and (3) switching to a different cytotoxic chemother-
apy agent after induction therapy.
With respect to molecularly targeted therapies, the
options include (1) continuing the same targeted therapy that
was delivered concurrently with induction chemotherapy af-
ter completion of four to six cycles of chemotherapy, (2)
introducing a second molecularly targeted agent after com-
pletion of the chemotherapy phase, and (3) switching to a
new targeted agent, after chemotherapy. In addition, there is
interest in inducing the immune system after induction che-
motherapy, using immunotherapy.
In most trials, maintenance therapy was offered only to
patients who had demonstrated complete response (CR) or
partial response (PR) or who had achieved stable disease
(SD) status in response to four cycles of induction chemo-
therapy. We have not included studies of “consolidation”
chemotherapy after definitive chemoradiation for locally ad-
vanced stage IIIA and “dry” IIIB NSCLC, because these
studies usually administered only a short course (2–3 cycles)
of chemotherapy after radiation and were not designed as
long-term maintenance trials. Thus, the focus of this review is
mainly on advanced NSCLC, and data presented are from
large randomized phase III studies where possible. We have,
however, included details of smaller studies, where there is a
paucity of higher quality data.
MATERIALS AND METHODS
PubMed was searched using the following key words:
non-small cell lung cancer, chemotherapy, maintenance, pro-
longed, erlotinib, gefitinib, cetuximab, and antiangiogenic.
The proceedings of American Society of Clinical Oncology
annual meetings and the proceedings of World Conferences
on Lung Cancer from 2003 to 2009 were searched using the
same keywords. Preference was given to phase III studies.
We limited our search to those articles written in the English
language.
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RESULTS
Continuation of First-Line Induction
Chemotherapy
The American Society of Clinical Oncology guideline
for the treatment of advanced NSCLC recommends platinum-
based chemotherapy to be administered for no more than six
cycles in patients with stage IV NSCLC.3 This recommenda-
tion was based on the results of randomized trials that
compared shorter versus longer periods of administration of
platinum-based chemotherapy.
The largest randomized trials that compared the admin-
istration of different numbers of cycles of the initial cytotoxic
chemotherapy regimen are summarized in Table 1.4–7 The
studies varied with respect to the number of cycles in the
“standard” arm (three gave 3 cycles and one gave 4 cycles),
and three trials administered six cycles in the experimental
arm. Only one trial employed a true “maintenance” approach
in the experimental arm with continuation of chemotherapy
until progression. There are a number of small studies, or
studies reported only in abstract form that use this trial design
outline,8–10 but we have chosen to review in detail only the
phase III, peer-reviewed reports.
Socinski et al.4 performed a phase III study of 230
patients examining treatment with four cycles of carboplatin
and paclitaxel versus carboplatin and paclitaxel until progres-
sion. All patients were to receive second-line weekly pacli-
taxel upon progression. The coprimary end points of this
study were overall survival (OS) and quality of life (QoL).
Interestingly, the median number of treatment cycles on both
arms was four, although in the investigational arm, 42%
patients received more than four cycles and 18% received
eight or more cycles. Furthermore, in the patients randomized
to receive four cycles of chemotherapy, only 57% of patients
received the full four cycles of treatment planned. The me-
dian survival of patients randomized to receive four cycles of
chemotherapy and chemotherapy until progression was 6.6
and 8.5 months, respectively (p  0.63). Regarding QoL,
there were no statistical differences between baseline and
week 11 QoL scores. There were no significant differences in
toxicity between the two arms, with the exception of neuro-
toxicity. As might be expected, given the recognized side
effect profile of paclitaxel, there was significantly more grade
2 to 4 neurotoxicity experienced by patients randomized to
continue chemotherapy past four cycles (27% versus 14%,
p  0.02). The authors concluded that there was no benefit to
extending chemotherapy beyond four cycles of treatment.
Smith et al.5 compared three to six cycles of mitomy-
cin, vinblastine, and cisplatin in 308 patients. Only 72% of
patients randomized to receive three cycles of chemotherapy
completed treatment and less than one-third of patients (31%)
received all six cycles of chemotherapy in the experimental
arm. Median time to disease progression (TTP) was 5 months
for both arms (p  0.4), and there was no difference in OS
(p 0.2). There were no differences in QoL between the two
groups for the first 9 weeks of treatment, but during weeks 9
to 18, patients continuing on chemotherapy reported signifi-
cantly more fatigue (p  0.03).
von Plessen et al.6 randomized 300 patients to receive
either three or six cycles of carboplatin and vinorelbine. As in
the study by Smith et al., only 78% of patients received all
three cycles of chemotherapy in the three-cycle arm, and only
54% of patients received all six cycles of chemotherapy in the
six-cycle arm. Although median progression-free survival
(PFS) and OS favored the six-cycle arm, the differences were
not significant (p 0.21 for PFS and p 0.75 for OS). At 18
and 26 weeks follow-up, there were no differences between
the groups in palliation of fatigue, pain, or global QoL.
Park et al.7 performed a study of slightly different
design in which 218 Korean patients were randomized to
receive either two or four additional cycles of third-genera-
tion, platinum-based chemotherapy, after response to only
two induction cycles of chemotherapy. This was a noninfe-
riority study, with OS as its primary end point. This study was
designed to demonstrate noninferiority in 1-year survival rate
with only two additional cycles, using a noninferiority margin
of 15%. Again, there was a disparity seen in terms of
completed cycles, with 68.4% of patients receiving all six of
their planned cycles of chemotherapy, compared with 92.3%
TABLE 1. Trials of Prolonged Platinum-Based Doublet Chemotherapy for Non-small Cell Lung Cancer
Trial Treatment Arms
Number
Randomized
Response
Rate (%)
Progression-Free
Survival
Overall
Survival p
Socinski et al.4 Four cycles of carboplatin/paclitaxel 114 22 NR 6.6 mo 0.63
vs.
Carboplatin/paclitaxel until progression 116 24 NR 8.5 mo
Smith et al.5 Three cycles mitomycin, vincristine, and cisplatin 155 31 5 mo 6 mo 0.2
vs.
Six cycles mitomycin, vincristine, and cisplatin 153 38 5 mo 7 mo
von Plessen et al.6 Three cycles carboplatin/vinorelbine 150 NR 16 wk 28 wk 0.75
vs.
Six cycles carboplatin/vinorelbine 147 NR 21 wk 32 wk
Park et al.7 Four cycles third-generation platinum doublet 156 41.6 4.6 mo 15.9 mo 0.46
vs.
Six cycles third-generation platinum doublet 158 47.5 6.2 mo 14.9 mo
NR, not reported; QoL, quality of life.
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of patients receiving all four planned cycles. The difference
in the 1-year survival rate between the two groups was 3.4%
(95% CI, 8.0 to 14.8) and met the predefined criterion for
noninferiority. Median TTP was significantly longer at 6.2
months in the six-cycle group, compared with 4.6 months in
the four-cycle group (p  0.001), although there was no
difference in OS, with median survivals of 14.9 and 15.9
months (p  0.461). The authors of this study postulated that
the lack of translation to OS benefit may have been due to a
dilution effect from second-line chemotherapy, because
62.7% and 74.4% of the six and four cycle groups, respec-
tively, received second-line treatment (p  0.26). Toxicity
rates were similar in both arms. However, QoL analyses
revealed that during the time from the completion of cycle 4
to 3 months later, patients treated with four cycles of chemo-
therapy showed significant improvement in role functioning,
compared with those receiving six cycles (p 0.05). Patients
in the four-cycle arm also experienced less nausea and vom-
iting, mucositis, and dyspnea, than those receiving six cycles
(p  0.05).
It is important to note that the difference in this study,
compared with previous studies, is that only patients who
responded after two cycles were randomized to continue.
This probably explains the overall higher proportion of pa-
tients who went on to receive their full complement of
planned chemotherapy, and survived longer, in this study,
compared with previous studies. The observation that TTP
was increased in responding patients provided the impetus for
researchers to investigate whether maintenance therapy in
stable and responding patients, particularly with more easily
tolerated drugs, could result in a benefit in OS.
Continuing First-Line Single-Agent Induction
Chemotherapy without the Platinum Analogue
It is widely accepted that toxicity from platinum-based
doublet chemotherapy is derived mainly from the platinum
component, and that most patients cannot tolerate prolonged
administration of platinum-based doublets. Nevertheless, the
same does not seem to be the case for third-generation
single-agent treatment, as demonstrated in the trials of sec-
ond-line therapy. In the TAX31711 and TAX320 studies,12 as
well as trials comparing docetaxel to topotecan13 or pem-
etrexed,14 the median number of cycles administered was
only 3 to 4. However, treatment was allowed to continue to
progression or unacceptable toxicity in all of these studies,
resulting in an upper range of 14 to 28 cycles in some
patients! In view of this degree of tolerability, a recent
strategy has been to investigate the value of continued treat-
ment of responding and stable patients with the nonplatinum
component of their induction regimen. Trials of this design
are summarized in Table 2.
The Central European Cooperative Oncology Group
conducted a phase III randomized, multicenter study in
350 patients with advanced NSCLC to evaluate the effect
of gemcitabine maintenance therapy, after gemcitabine and
cisplatin initial therapy.15 The primary end point of this
study was TTP with secondary end points of overall
response rate (ORR), response duration, OS, toxicity, and
symptom control. Patients who responded (defined as
achieving CR, PR, or SD) after four cycles of induction
therapy were randomized in a 2:1 fashion to receive
maintenance gemcitabine plus best supportive care (BSC)
or BSC alone. It should be noted that the Southwest
Oncology Group criteria for response, rather than the more
stringent and widely accepted Response Evaluation in
Solid Tumors (RECIST), were used. Objective response or
SD was seen in 257 patients (73%), but only 215 patients
(61%) were randomized to gemcitabine maintenance or
BSC. Ultimately, 138 patients received maintenance gem-
citabine and 68 received BSC. During the maintenance
period, patients received a median of three cycles of
gemcitabine (range, 0 –38 cycles). The median TTP
throughout the study was significantly longer on the gem-
TABLE 2. Continuing the Nonplatinum Compound After Induction Treatment for Non-small Cell Lung Cancer
Trial Patient Population
Total
Patients
Treatment
Arms
Number
Randomized
Response
Rate (%)
Progression-Free
Survival
Overall
Survival p
Brodowicz et al.15 Patients who did not
progress after 4
cycles of cisplatin
and gemcitabine
354 Maintenance
gemcitabine
138
gemcitabine
50.7 6.6 mo 13 mo 0.001
vs.
Best supportive
care
68 BSC 45.6 5 mo 11 mo
Belani et al.16 Patients who
responded after 16
wk on 1 of 3
differing regimens
of carboplatin and
paclitaxel
401 Maintenance
paclitaxel
vs.
Observation
65 paclitaxel
65 observation
NR 38 wk
29 wk
75 wk
60 wk
NR
POI-01-003-050 Patients who did not
progress after 4
cycles of
carboplatin and
gemcitabine
600 Maintenance
gemcitabine
332 have been
randomized
NR NR NR NR
vs.
Best supportive
care
NR, not reported.
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citabine arm, 6.6 months versus 5 months on BSC (p 
0.001). For the maintenance period, patients on mainte-
nance gemcitabine also had a significantly longer TTP of
3.6 months versus 2 months (p  0.001). Patients with a
better performance status had significantly longer TTP,
both throughout the study and during the maintenance
period. The median OS on the gemcitabine arm was 13
months, compared with 11 months on the BSC arm (p 
0.195). The most notable difference between the gemcit-
abine arm and the BSC arm during the maintenance phase
of this study was the need for transfusion (20% of gem-
citabine patients versus 6.3% on BSC, p  0.018). Of note,
maintenance gemcitabine was well tolerated and did not
result in deterioration in QoL, compared with BSC.
In a North American study,16 401 patients were treated
with differing schedules of carboplatin and paclitaxel induc-
tion therapy for 16 weeks. Responding patients were then
randomly assigned to receive maintenance single-agent pac-
litaxel, 70 mg/m2 weekly, or BSC. The primary end point of
this study was TTP. Response was seen in 130 of 390
evaluable patients who were then deemed eligible for ran-
domization in the maintenance phase. Of the patients ran-
domized to the treatment arm, 80% completed one full cycle
of paclitaxel, but only 23% completed four cycles. The most
common reasons for discontinuing paclitaxel were disease
progression and adverse events. Median TTP in the paclitaxel
arm was 38 weeks versus 29 weeks in the observation arm
(p  0.124) with median survival times of 75 and 60 weeks
(p 0.243), respectively. The 1-year survival rates were 72%
and 60% in the paclitaxel and observation arms, respectively,
with 2-year rates of 32% and 26% (p value not reported).
During maintenance therapy, 86% of patients in the treatment
group experienced at least one adverse event, and 45%
reported at least one grade 3 or 4 adverse event. The authors
of this study concluded that although the results were pro-
vocative, the sample size was too small to draw definitive
conclusions regarding the clinical utility of low-dose main-
tenance paclitaxel.
A much larger study randomizing patients responding
to initial therapy with carboplatin and gemcitabine to main-
tenance gemcitabine has completed accrual and results are
awaited. Six hundred patients have been recruited, and 332
were randomized to either maintenance gemcitabine or BSC.
The end point of this trial is OS, and hence it is expected that
more definitive conclusions may be drawn from this study.
Switching to a New Chemotherapy Agent in
Responding and Stable Patients
A long upheld tenet of medical oncology practice
relates to the Goldie-Coldman hypothesis17 that even the
smallest detectable cancers contain at least one drug-resistant
clone and that increasing numbers of resistant clones emerge
as tumors grow and progress. Therefore, the best chance of
cure would be to use all effective chemotherapy drugs as
early as possible in the treatment course. In practice, this has
meant using two different non–cross-resistant chemotherapy
regimens in alternating cycles. This strategy has been used
in the design of recent maintenance trials in NSCLC in
which patients are treated with one schedule of induction
chemotherapy and then switched to an alternative, non–
cross-resistant agent if they respond to or remain stable on
initial therapy.
A French study used this design in a trial of 573
patients with stage IIIB and IV NSCLC who were treated
initially with mitomycin, ifosfamide, and cisplatin (MIC).18
Those with stage IIIB disease received two cycles of chemo-
therapy followed by radiation (55–60 Gy in 30 fractions), and
those with “wet” IIIB and IV disease received four cycles
of MIC (Table 3). Of 227 patients who responded, 181 were
randomized to receive maintenance treatment with weekly
TABLE 3. Trials Introducing New Chemotherapeutic Agents as Maintenance After Induction Therapy for Non-small Cell Lung
Cancer
Study Patient Population
Total
Patients Treatment Arms
Number
Randomized
Response
Rate (%)
Progression-Free
Survival
Overall
Survival p
Westeel et al.18 Patients responding to
4 cycles of MIC
(stage wet IIIB/IV)
or 2 cycles of MIC
following radiation
therapy (stage III)
573 Vinorelbine
vs.
Observation
91 vinorelbine
90 observation
NR 5 moa
3 moa
12.3 mo
12.3 mo
0.65
Fidias et al.19 Patients who did not
progress after 4
cycles of induction
carboplatin and
gemcitabine
566 Docetaxel immediately
following induction
vs.
Docetaxel administered
at time of
progression
153 immediate
treatment
156 treatment at
progression
11.7
11.2
5.7 mo
2.7 mo
12.3 mo
9.7 mo
0.85
Belani et al.21 Patients who did not
progress after 4
cycles induction
therapy with a
platinum doublet
660 Pemetrexed
vs.
Placebo
441 pemetrexed
222 placebo
51.7b
33.3b
4.3 mo
2.6 mo
13.4 mo
10.6 mo
0.01
a From date of randomization.
b Disease control rate.
NR, not reported.
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vinorelbine for 6 months or BSC. The mean duration of
therapy was 13.8 weeks, and only 23% of patients completed
the full 6 months of vinorelbine. The most common reasons
for stopping chemotherapy prematurely were progressive
disease (38%) and treatment toxicity (21%). The median
survival in both groups was 12.3 months (p  0.48), and the
hazard ratios (HRs) for PFS and OS, after adjustment for
stage in the vinorelbine arm relative to the observation arm,
were 0.77 (p  0.11) and 1.08 (p  0.65), respectively.
Median PFS from the date of randomization was 5 months in
the vinorelbine group and 3 months in the observation group
(p  0.32). Differential toxicity between the treatment arms
was not reported. However, the use of MIC chemotherapy
with radical radiotherapy might be expected to be more toxic
than standard platinum doublet chemotherapy alone. This
may explain the high percentage of patients who discontinued
therapy early, both because of toxicity and patient choice.
A more recent study compared the administration of
docetaxel immediately after completion of carboplatin and
gemcitabine induction chemotherapy with observation and
docetaxel given only at the time of documented progres-
sion.19 After four cycles of gemcitabine and carboplatin, 309
of 566 patients were deemed to be “nonprogressors” and
randomized to either immediate or delayed docetaxel. Of the
patients randomized to immediate docetaxel, 94.8% of pa-
tients received at least one treatment cycle, whereas only
62.8% of patients randomized to delayed treatment ever
received docetaxel. The most common reasons for not receiv-
ing docetaxel on the delayed arm, were disease progression,
patient or investigator decision, and death. The median num-
ber of cycles of docetaxel administered on both arms of the
study was 4.4. PFS was significantly longer for patients
treated immediately (HR not reported, p  0.0001). OS also
favored the immediate docetaxel arm (median 12.3 versus 9.7
months [HR not reported]), although the difference did not
reach statistical significance (p  0.0853). There were no
differences in toxicity or QoL between the two treatment
groups. The marked discrepancy in the number of patients
receiving the planned treatment in the delayed arm was felt
by the authors to be due to declining performance status at the
time of progression that precluded further treatment. When
the survival of the patients who actually received docetaxel in
the delayed arm was compared with that of the treated
patients in the immediate arm, no major differences were
seen. This suggests that when patients stop first-line chemo-
therapy, they should be followed closely to detect progression
early and at a time when they remain fit for further treatment.
The fact that the improvement in PFS did not translate into a
significant improvement in OS may simply be a result of the
fact that the study was underpowered to detect a significant
difference.
Pemetrexed has been shown to be noninferior to do-
cetaxel in the second-line treatment of NSCLC and better
tolerated.14 The drug has also been shown to be well tolerated
in the first-line treatment of nonsquamous NSCLC in com-
bination with a platinum analogue.20 The JMEN study com-
pared maintenance chemotherapy with pemetrexed to pla-
cebo, in stable and responding patients treated initially with
one of three platinum-based induction chemotherapy regi-
mens.21 Patients who did not progress were randomized in a
2:1 ratio to receive either pemetrexed or placebo, adminis-
tered on a 21 day cycle. The primary end point was PFS.
There were 660 patients randomized and a prespecified anal-
ysis by histology was incorporated into the protocol. Of the
patients randomized to pemetrexed, 48% received 6 cycles
of chemotherapy and 23% received 10 cycles of chemo-
therapy. There was a significant PFS advantage seen in the
group as a whole (HR 0.6, p  0.00001). Subgroup analysis
revealed that patients with nonsquamous histology had a HR
of 0.47 (p  0.00001, interaction p value 0.036). When OS
was examined, there was a significant advantage seen in the
entire treatment group (HR 0.79, p  0.012). Furthermore,
patients with nonsquamous tumors had a median survival
advantage of 5 months (15.5 months versus 10.3 months) and
a significant OS benefit (HR 0.7, p  0.002, interaction p
value 0.033). There were no significant differences in QoL,
and toxicity was modest. In the placebo arm, only 19%
patients went on to receive pemetrexed at any future point.
This means that conclusions regarding earlier versus later
administration of pemetrexed cannot be drawn from this trial.
However, the survival advantage in patients with nonsqua-
mous tumors is compelling, and in such patients who derive
good symptom control from the initial administration of
chemotherapy, this may be an acceptable treatment paradigm.
Two major drug regulatory bodies, the European Medicines
Agency and the Federal Drug Authority, have approved
pemetrexed as maintenance chemotherapy in nonsquamous
NSCLC.
Maintenance Therapy with Molecularly
Targeted Agents
Several molecularly targeted agents are approved for
the treatment of NSCLC, most notably, agents targeting
angiogenesis22 and the epidermal growth factor (EGF) path-
way.23 In the first-line setting, bevacizumab, a monoclonal
antibody that targets vascular endothelial growth factor
(VEGF), and cetuximab, an antibody that targets the EGF
receptor (EGFR), have been studied in large randomized
trials. Modest improvements in ORR, PFS, and OS have been
demonstrated in most studies with the addition of these agents
to platinum-based chemotherapy doublets.24,25 All studies
were designed to continue maintenance antibody therapy in
responding and stable patients after completion of chemo-
therapy. Whether this is necessary, or whether it simply adds
to cost and the potential for toxicity, is unknown at this time,
because there have been no trials in which responding and
stable patients were randomized either to stop or to continue
treatment. The EGFR tyrosine kinase inhibitors (TKIs) ge-
fitinib and erlotinib have been shown to prolong survival
when administered as second-line or third-line therapy in
advanced NSCLC.26 More recently, they have been evaluated
as maintenance therapy in earlier stages of NSCLC. The
phase III studies of molecularly targeted maintenance therapy
are summarized in Table 4.
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Maintenance Therapy with EGFR Inhibitors
After Induction Chemotherapy
Concurrent administration of erlotinib and gefitinib
with chemotherapy was evaluated as part of their drug de-
velopment programs, but their addition to cytotoxic therapy
failed to show benefit even though the oral EGFR TKIs were
continued as maintenance after chemotherapy in all tri-
als.27–30 Despite this, however, integrating the administration
of these agents with cytotoxic chemotherapy as part of a
maintenance treatment paradigm has been of interest. Unlike
other agents that have been investigated in the maintenance
setting, the EGFR TKIs are administered orally and have
fewer side effects relative to cytotoxic chemotherapy.
The sequential Tarceva® in unresectable non-small cell
lung cancer trial (SATURN) was a large international study
in which 1949 patients were treated initially with four cycles
of platinum-based chemotherapy.31 Those who did not
progress on treatment (n  889) were randomized to receive
either maintenance erlotinib or placebo. The primary end
point was PFS, and the patients were stratified by a number of
clinical factors as well as EGFR protein expression status
assessed by immunohistochemistry and EGFR gene copy
assessed by fluorescent in situ hybridization. Both PFS and
OS were significantly longer in the erlotinib arm (HR for PFS
0.71, p  0.0001; HR for OS 0.81, p  0.0088). Biomarker
analysis showed that there was no significant interaction for
EGFR protein expression or EGFR copy number. However,
patients with EGFR sensitizing mutations in exons 19 or 21
derived significantly greater PFS benefit from maintenance
erlotinib (HR 0.10, p 0.0001) compared with those patients
with EGFR wild-type tumors (HR 0.780, p  0.018). Fur-
thermore, the treatment by mutation interaction test was
highly significant (interaction p  0.001). In contrast, how-
ever, these biomarkers did not predict for a differential OS
benefit, likely due to cross-over to erlotinib treatment at the
time of progression.
Erlotinib maintenance has also been studied in the
first-line setting after induction therapy with paclitaxel/car-
boplatin and the VEGF monoclonal antibody bevacizumab in
a study comparing bevacizumab therapy with or without
erlotinib after completion of chemotherapy for advanced
NSCLC—the ATLAS trial.32 In this global study, 743 stable
and responding patients remained on maintenance bevaci-
zumab and were randomized to receive oral erlotinib 150 mg
daily or placebo. PFS was significantly longer in the erlotinib
arm (HR 0.72, p  0.001), although the magnitude of the
absolute difference in median PFS was only 1 month. The
PFS improvement was seen across multiple subgroups, in-
cluding those defined by sex, histology, age, and smoking
status; molecular subgroup analyses have not been reported.
OS results are awaited.
Gefitinib also has been assessed as a maintenance
treatment in two randomized trials. The European Organiza-
tion for the Research and Treatment of Cancer 08021 trial
was similar in design to the SATURN study. Initially, all
stable and responding patients were eligible for study, but the
protocol was amended to require evidence of EGFR protein
expression by immunohistochemistry. This resulted in aTA
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slowing of recruitment, which ultimately led to study closure
before it reached its target accrual. In the Southwest Oncol-
ogy Group 0023 trial, patients with inoperable stage III
NSCLC received induction etoposide and cisplatin chemo-
therapy administered concurrently with thoracic radiation,
followed by consolidation single-agent docetaxel.33 Respond-
ing and stable patients then were randomized to receive oral
gefitinib (initially 500 mg daily and subsequently 250 mg
daily) maintenance or placebo. This trial was stopped early
by the data and safety monitoring committee when survival in
the active treatment arm was found to be inferior to that of
patients on placebo. The authors suggested three possible
reasons for this. (1) There were no molecular correlates
reported in this study, and the authors suggested there may
have been an undetected imbalance in molecular character-
istics between the arms. (2) The authors postulated that
poststudy treatments may have been different between the
two treatment arms, but this was not recorded on this study
and no definitive conclusions can be drawn. (3) Radiation
was used in this study, which may change EGFR pathway
signaling, resulting in the observed inferior survival seen in
the gefitinib arm. Without the requisite information to draw
these conclusions, it remains difficult to interpret the meaning
of this study; however, given the fact that maintenance EGFR
TKI in other settings has shown efficacy, the argument that
radiation given before administration may in some way alter
signaling through the EGFR pathway seems plausible.
Recently, three randomized trials have compared first-
line treatment with EGFR TKIs with combination chemother-
apy in clinically selected populations,34–36 and one trial has
compared gefitinib with chemotherapy in Asian patients with
EGFR sensitizing mutations in exons 19 and 21.37 All these
trials have demonstrated a PFS advantage for patients treated
with the EGFR TKI. In the trials that selected patients based
on clinical characteristics, EGFR molecular profiling studies
in a subset of patients revealed that the benefit was greatest in
patients whose tumors harbored sensitizing EGFR muta-
tions. On closer examination of the survival curves in these
studies, it seems that in the sensitive populations, the
curves track closely together during the first few months
and only start to separate at the approximate time that
chemotherapy would cease in the chemotherapy arms. This
observation perhaps suggests that the PFS benefit seen in
the EGFR TKI arms may have been due to the prolonged
administration of the well-tolerated oral agent, or in other
words, maintenance therapy.
Maintenance Therapy with Angiogenesis
Inhibitors After Induction Chemotherapy
The ability of a tumor to initiate and maintain its own
blood supply is a hallmark of cancer.38 Therefore, agents that
interrupt this process have long been a focus of oncological
therapeutic research. Two trials comparing chemotherapy
alone with chemotherapy plus bevacizumab, a monoclonal
antibody directed against VEGF, showed improvements in
ORR and PFS.24,39 In both studies, bevacizumab continued in
responding and stable patients after completion of chemo-
therapy. In the Eastern Cooperative Oncology Group 4599
trial,24 of the 407 patients starting treatment with chemother-
apy and bevacizumab, 215 (53%) continued with bevaci-
zumab monotherapy, and of these patients, 107 (50%) re-
ceived more than five cycles in this maintenance phase. In the
second large bevacizumab trial,39 351 patients were random-
ized to receive high-dose (15 mg/kg) and 345 to low-dose
(7.5 mg/kg) bevacizumab. The percentages of patients com-
pleting six cycles of chemotherapy and bevacizumab were
49% in the low-dose and 45% in the high-dose bevacizumab
groups. Of these, 42% and 41% of patients continued single-
agent bevacizumab as maintenance treatment after comple-
tion of induction therapy. In fact, 94% of patients eligible to
receive single-agent bevacizumab were still receiving main-
tenance therapy at cycle 7.
It is impossible to determine whether or what prop-
ortion of the PFS benefit in the bevacizumab arms of these
two trials might have come from the maintenance phase of
the treatment as neither trial was designed to answer this
question. Indeed, the entire PFS and OS benefits of bevaci-
zumab may have come from the higher response rates in the
bevacizumab arms reported in all studies and may not have
been due to the prolonged administration of this agent.
Considering the potential for toxicity and the cost of this
drug, the issue of maintenance therapy with bevacizumab is
one that deserves further attention.
As discussed above, the ATLAS study32 evaluated the
addition of the oral EGFR TKI erlotinib to bevacizumab after
induction chemotherapy. Although there was a statistically
significant difference in PFS between the bevacizumab/erlo-
tinib arm and the bevacizumab/placebo arm, with a HR of
0.722 (p  0.0012), this was at the expense of added toxicity
observed in the bevacizumab/erlotinib arm.
In addition to the monoclonal antibodies, there are a
number of oral angiogenesis inhibitors directed against
VEGF receptor tyrosine kinases, which have been investi-
gated in combination with chemotherapy. All trials per-
formed to date continued the oral angiogenesis inhibitor after
treatment with chemotherapy in responding and stable pa-
tients. No study has demonstrated a significant PFS or OS
benefit to date, and so, at this time, no conclusions can be
drawn concerning the potential for benefit from maintenance
therapy with these agents. However, the Cancer and Leuke-
mia Group B 30607 trial is designed to address this question.
In this randomized phase II study, patients receive four cycles
of platinum-based chemotherapy (bevacizumab is allowed in
eligible patients), and responding and stable patients are
randomized to receive sunitinib 37.5 mg daily or placebo
daily. The primary end point is PFS, and cross-over to
sunitinib is allowed at the time of progression. This study
does not administer sunitinib during the chemotherapy phase.
In a more advanced setting, the Eastern Cooperative
Oncology Group conducted a randomized discontinuation
design trial in previously treated patients (E2501). All pa-
tients received the oral VEGF response TKI sorafenib 400 mg
twice daily for 2 months.40 Responding and stable patients
then were randomized to receive sorafenib or placebo main-
tenance therapy. At the time of progression, patients on
placebo were allowed to receive sorafenib again. At the
2-month evaluation point, 22% of placebo patients and 35%
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of sorafenib patients continued to have stable or responding
disease (p  0.01)with an overall benefit in PFS favoring
sorafenib maintenance treatment (HR 0.50, p  0.01). The
HR for OS also favored sorafenib, even though 61% of
patients on the placebo arm crossed over to sorafenib at the
time of progression (HR 0.68, p  0.15). This is the first
study to suggest that maintenance of response with a VEGF
TKI may prolong not only PFS but also OS. These results
require confirmation in a larger well-powered study.
Although this overview primarily has dealt with
NSCLC, there has been one study of maintenance therapy
with the dual EGFR and VEGF TKI vandetanib (Zactima,
ZD6474, AstraZeneca, Wilmington, DE) in responding and
stable patients with small cell lung cancer.41 In this NCIC
Clinical Trials Group BR.20 phase II study, 103 patients were
randomized to receive oral vandetanib 300 mg daily or
placebo. No benefit was observed for either PFS or OS.
However, in multivariate analysis, significant interaction was
noted for stage showing a benefit from vandetanib in the
limited disease subset.
Immunotherapy as Maintenance Therapy
Modulating the immune response in lung cancer is a
strategy that is being investigated in the maintenance setting
in NSCLC. Initial attempts to modulate the immune system in
lung cancer were unsuccessful; however, some of the newer
agents have shown promise recently and are undergoing
evaluation in phase III studies.42 One agent of interest in this
setting is the compound L-BLP25 (Stimuvax; Biomira, Al-
berta, CA). This is a liposome vaccine targeted to the extra-
cellular core peptide of mucin 1 (MUC1). MUC1 is a trans-
membrane protein expressed on epithelial cells. The function
of MUC1 is not known, but in some studies, it has been
shown to be a poor prognostic factor in solid tumors. In a
randomized phase 2B trial of L-BLP25, patients with stage
III/IV NSCLC who had SD, or who had responded to induc-
tion chemotherapy, were randomized to receive vaccination
weekly for 8 weeks.43 They had the option to proceed to
maintenance therapy, consisting of vaccination every 6 weeks
starting during week 13, or BSC. All patients received a
single infusion of cyclophosphamide 3 days before vaccine
administration in an attempt to reduce activity of suppressor
T cells. The primary end point was OS. There were 88
patients in the BSC arm and 83 in the vaccine arm. The
treatment was well tolerated; 96.6% of patients completed the
initial 8 injections, and 69.3% patients proceeded to mainte-
nance vaccine. The median OS was 17.4 months for the
vaccinated patients versus 13.0 months for those on BSC arm
(p  0.66). An unplanned exploratory analysis revealed that
patients with locoregional stage IIIB disease randomized to
vaccine had improved survival compared with those random-
ized to BSC (HR 0.52, p  0.69). For this reason, a large
international placebo-controlled trial of L-BLP25 vaccine in
patients treated with chemoradiation for locally advanced
stage III NSCLC is now underway—the Stimulating Targeted
Antigenic Responses To NSCLC trial (START).44
Belagenpumatucel-L (Lucanix; NovaRx Corporation,
San Diego, CA) is developed from allogeneic NSCLC cell
lines, which have been genetically modified to secrete anti-
sense oligonucleotide to transforming growth factor-2.
Transforming growth factor-2 is an immunosuppressant that
has been described as a poor prognostic factor in NSCLC.45
A randomized phase II study of this drug recruited 75 patients
with stage II to IV NSCLC, after induction therapy (or patient
refusal of induction therapy).46 Patients were randomized to
one of the three dose levels. Patients receiving the highest
dose had a median survival of 581 days, compared with 252
days for those on the lowest dose. This vaccine is now in
phase III testing in the maintenance setting in patients with
advanced disease who have not progressed on standard first-
line induction chemotherapy as the Phase III Lucanix™
Vaccine Therapy in Advanced Non-small Cell Lung Cancer
(NSCLC) Following Front-line Chemotherapy (STOP).47
DISCUSSION
A recent meta-analysis48 confirmed that maintenance
chemotherapy in NSCLC improved PFS; less clear was the
effect of maintenance chemotherapy on OS. It is worth
noting, however, that this meta-analysis did not include any
trials of molecularly target agents, and it included some trials
discussed above that used relatively outmoded and toxic
therapies.
In reality, when the survival benefit derived by uns-
elected patients in maintenance chemotherapy and mainte-
nance molecular therapy trials is examined critically, the
benefits must be considered modest, at best, particularly when
offset against the cost, toxicity, and inconvenience for pa-
tients. However, the data become somewhat more compelling
when the results are examined in specific patient subsets. For
example, in the trial by Belani et al.,21 the median survival
benefit was only 2.8 months, with a HR of 0.79 (CI 95%
0.65–0.95), in patients treated with maintenance pemetrexed
therapy. However, when the subgroup of patients with
nonsquamous histology was examined, the median survival
advantage for the treated group increased to 5.2 months, with
a HR of 0.70 (95% CI, 0.56–0.88). This median survival
benefit is larger than that reported in any other studies to date
for any chemotherapeutic or molecularly targeted agent in the
first-line treatment of NSCLC, and so it cannot be ignored.
Furthermore, maintenance pemetrexed was well tolerated,
and maintenance therapy was not associated with deteriora-
tion in QoL in this study. Thus, this may present an attractive
treatment strategy for patients with nonsquamous histology,
but before its wide-spread acceptance, further study of the
cost implications of this approach must be undertaken.
It is interesting that in the trial by Fidias et al.,19
patients in the safety population who actually received sec-
ond-line therapy with docetaxel in the “delayed” arm had the
same OS as those patients receiving chemotherapy up front.
The relative “fall-off” of patients from the delayed group was
what caused the delayed group to do less well than those
treated up front. This suggests that although there are some
patients who safely may receive a treatment holiday after
successful induction therapy, other patients will progress
quickly after discontinuation of treatment, and a declining
performance status as a result of progressive disease may
result in those patients never receiving second-line therapy.
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At present, there are no definitive markers of risk that allow
us to identify who these patients might be, but this should be
a focus of future research. None of the studies has reported
whether patients who achieved confirmed CR or PR status
derived greater OS or PFS benefit from maintenance therapy
than those who achieved only SD. Furthermore, none of the
studies has identified whether degree of response to induction
therapy predicts for the likelihood of receiving second-line
treatment at the time of progression.
In patients for whom a drug holiday may be appropri-
ate, how long should the holiday be? How best should we
monitor patients during a break from treatment? Reaching
consensus as to what constitutes the optimal surveillance
regimen for those patients who would like a therapeutic break
and developing clinical or other biomarkers to predict those
patients who fall into a high-risk category for early progres-
sion are the two strategies that might go some way toward
addressing these therapeutic dilemmas. The converse is also
true, because it is difficult to defend exposing patients to
treatment toxicity from maintenance chemotherapy if they, in
fact, have relatively indolent tumors.
The need to balance benefit and risk is always para-
mount in oncology, where the therapeutic index is the nar-
rowest of all in clinical medicine. The way in which toxicity
is graded is borne from experience of adverse events endured
as part of a relatively intense but finite course of treatment. In
the maintenance setting, our willingness as clinicians to risk
patient exposure to adverse events and the patients’ willing-
ness to accept toxicity may be less, particularly if toxicity
may last for months or even years. This is particularly true
when the goal of treatment is not cure. What may be accept-
able for a number of days as a grade 2 adverse event,
experienced a total of six times on a cytotoxic chemotherapy
regimen, may not be viewed as acceptable if experienced on
an ongoing seemingly endless basis. The degree of toxicity is
captured in most trials in a dispassionate objective format.
What is often not collected or reported is the effect that
toxicity has on patient’s QoL. Therefore, it is critical that all
trials of maintenance therapy collect prospective QoL data.
The issue of cost, particularly in these times of global
fiscal crisis, and constant political debate in many jurisdic-
tions over health care reform is one that is crucial in any
discussion of prolonged, potentially costly treatment. The
“one-size-fits all” approach of treating all unselected patients
with expensive chemotherapy or molecularly targeted thera-
pies is arguably the approach that is most likely to result in
unfavorable pharmacoeconomic profiles for those treatments.
To date, most cost-effective analyses have been performed
retrospectively, and frequently detailed data have been ab-
stracted from chart review for only a subset of trial patients.
The most robust data for any type of analysis come from
prospective study, and so, just as with QoL information,
health resource utilization data that will allow meaningful
cost-effectiveness analyses (CEA) should be collected pro-
spectively in all future maintenance trials. However, a word
of caution is necessary when interpreting costs in clinically or
molecularly selected subsets of patients, because the cost-
effective ratio may not always be that which is expected. A
recent retrospective CEA by Bradbury et al.49 reported dif-
fering and favorable economic profiles in patients who dem-
onstrated known clinical and molecular markers of response
to treatment with erlotinib. Unexpectedly, however, the cost
per year of life gained was not the most favorable in patients
with sensitizing mutations in the EGFR gene. This was
because these patients derived relatively greater benefit and
stayed on treatment longer, thereby incurring considerably
higher drug acquisition costs. In view of this, a CEA of the
SATURN study would be of considerable interest. Therefore,
although the way forward almost undoubtedly lies in person-
alizing medicine, both to benefit the patients most likely to
respond and to spend our health dollar wisely, the true cost
savings may arise from not treating those patients who derive
no benefit or only marginal benefit.
The mode of treatment delivery is always a consider-
ation, and this is especially true when treatment is prolonged.
Patients may prefer oral agents rather than the inconvenience
of adhering to an intravenous administration schedule,50 and
utilization of oral agents may also mean cost savings from
allied costs associated with intravenous regimens.
CONCLUSION
The evolution of maintenance therapy has reached an
interesting point and we seem to be poised on the verge of a
paradigm shift. What constitutes the optimal maintenance
treatment strategy is yet to be determined, because there have
been no comparative trials of maintenance chemotherapeutic
agents against other chemotherapy drugs or against targeted
agents. Similarly, the duration of monoclonal antibody ther-
apy has yet to be studied in NSCLC, yet maintenance of these
agents has become standard of care after completion of
first-line chemotherapy. The trials of pemetrexed and ge-
fitinib suggest that we should be selecting patients based on
their clinical and molecular profiles to maximize patient
benefit and to reduce the risk of unnecessary toxicity and
cost. Retrospective analyses of the reported trials should try
to identify those patients at greatest risk from stopping
treatment. There is also a need for studies to evaluate patient
willingness to receive maintenance therapy, and for those
who select to discontinue therapy, there is a need for consen-
sus on surveillance algorithms.
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